Abstracts tagged "systemic sclerosis and thrombosis"

Abstract Number: 2919 • 2016 ACR/ARHP Annual Meeting
Prevalence of Antiphospholipid Antibodies and Their Clinical Associations in Systemic Sclerosis: Data from a French Cohort
Angélique Lemaire^1,2, Vincent Sobanski^2,3,4,5, Jonathan Giovannelli⁶, Eric Hachulla^1,2,4,5, Sylvain Dubucquoi^4,7, Marc Lambert^1,2,4,5, Pierre-Yves Hatron^1,2,6 and David Launay^1,2,4,5, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ²CHU Lille, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), F-59000 Lille, France, Lille, France, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, ⁴Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, Lille, France, ⁵Inserm, U995, F-59000 Lille, France, Lille, France, ⁶Univ Lille, CHU Lille, F-59000 Lille, France, Lille, France, ⁷CHU Lille, Laboratoire d’Immunologie, F-59000 Lille, France, Lille, France
Background/Purpose: Antiphospholipid antibodies (aPL) have been found in patients with various autoimmune and rheumatic diseases, including systemic sclerosis (SSc). However, in the absence of clinical…
Abstract Number: 3009 • 2015 ACR/ARHP Annual Meeting
Fli1 Deficiency Contributes to the Downregulation of Endothelial Protein C Receptor in Systemic Sclerosis: A Possible Role in Pro-Thrombotic Condition
Ryosuke Saigusa¹, Yoshihide Asano², Takashi Taniguchi², Takashi Yamashita², Takehiro Takahashi², Yohei Ichimura², Tetsuo Toyama², Ayumi Yoshizaki², Tomomitsu Miyagaki², Makoto Sugaya² and Shinichi Sato², ¹7-3-1 Hongo, Bunkyo-ku, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a multisystem connective tissue disease characterized by fibrosis of the skin and certain internal organs due to the constitutive activation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].